Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: A new class of KDR kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 12, Issue 19, 2002, Pages 2767-2770

  Fraley, Mark E ^a   Hoffman, William F ^a   Rubino, Robert S ^a   Hungate, Randall W ^a   Tebben, Andrew J ^a   Rutledge, Ruth Z ^a   McFall, Rosemary C ^a   Huckle, William R ^a   Kendall, Richard L ^a   Coll, Kathleen E ^a   Thomas, Kenneth A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUNCTIONAL GROUP; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLONE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MITOGENS; PYRAZOLES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 18644368173     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00525-5     Document Type: Article

References (22)

1. Adamis A.P., Shima D.T., Yeo K.T., Yeo T.K., Brown L.F., Berse B., D'Amore P.A., Folkman J. Biochem. Biophys. Res. Commun. 193:1993;631.
2. Giatromanolaki A., Sivridis E., Athanassou N., Zois E., Thorpe P.E., Brekken R.A., Gatter K.C., Harris A.L., Koukourakis I.M., Koukourakis M.I. J. Path. 194:2001;101.
3. Detmar M. Dermatol. Sci. 24:2000;S78.
4. For reviews, see (a) Carmeliet, P.; Jain, R. K. Nature 2000, 407, 249. (b) Folkman, J. Nature Med. 1995, 1, 27.
5. For reviews, see (a) Carmeliet, P.; Jain, R. K. Nature 2000, 407, 249. (b) Folkman, J. Nature Med. 1995, 1, 27.
6. (a) Hanahan, D.; Folkman, J. Cell 1996, 86, 353.
7. (b) Holmgen, L.; O'Reilly, M. S.; Folkman, J. Nature Med. 1995, 1, 149.
8. (a) Veikkola, T.; Karkkainen, M.; Claesson-Welsh, L.; Alitalo, K. Cancer Res. 2000, 60, 203.
9. (b) Thomas, K. A. J. Biol. Chem. 1996, 271, 603.
10. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Nature. 362:1993;841.
11. Witte L., Hicklin D.J., Zhu Z., Pytowski B., Kotanides H., Rockwell P., Bohlen P. Cancer Metastasis Rev. 17:1998;155.
12. (a) Fong, T. A. T.; Shawyer, L. K.; Sun, L.; Tang, C.; App, H.; Powell, T. J.; Kim, Y. H.; Schreck, R.; Wang, X.; Risau, W.; Ullrich, A.; Hirth, K. P.; McMahaon, G. Cancer Res. 1999, 59, 99.
13. (b) Drevs, J.; Hofmann, I.; Hugenschmidt, H.; Wittig, C.; Madjar, H.; Müller, M.; Wood, J.; Martiny-Baron, G.; Unger, C.; Marmé, D. Cancer Res. 2000, 60, 4819.
14. For a current review, see Sun, L.; McMahon, G. Drug Discov. Today 2000, 5, 344.
15. (a) Muhmel, G.; Hanke, R.; Breitmaier, E. Synthesis 1982, 8, 673.
16. (b) Reichardt, C.; Ferwanah, A.-R.; Pressler, W.; Yun, K.-Y. Liebigs Ann. Chem. 1984, 649.
17. 1H NMR and mass spectroscopy.
18. 50 value represents biochemical inhibition of phosphorylation of a poly-Glu/Tyr (4:1) peptide substrate by isolated KDR kinase (cloned and expressed as a GST-fusion protein): see, Kendall, R. L.; Rutledge, R. Z.; Mao, X.; Tebben, A. J.; Hungate, R. W.; Thomas, K. A. J. Biol. Chem. 1999, 274, 6453.
19. Traxler P., Furet P. Pharmacol. Ther. 82:1999;195.
20. Fiaud J., Malleron J. Tetrahedron Lett. 21:1980;4437.
21. Winters G., Sala A., DePaoli A., Conti M. Synthesis. 1984;1050.
22. Partition coefficients were determined in octanol/water.